Latest dyskinesia Stories
DALLAS, April 17, 2015 /PRNewswire/ -- LifeScienceIndustryResearch.com adds Dyskinesia - Pipeline Review, H1 2015 and Dyskinesia Global Clinical Trials Review, H1, 2015
-- DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease NORTH CHICAGO, Ill., Jan.
MILAN, January 7, 2015 /PRNewswire/ -- - First New Chemical Entity (NCE) in 10 years to receive a positive opinion from CHMP for the treatment
MILAN, December 29, 2014 /PRNewswire/ -- Newron Pharmaceuticals S.p.A.
MILAN, December 19, 2014 /PRNewswire/ -- - First New Chemical Entity (NCE) in 10 years to receive a positive opinion from CHMP for the treatment
SAN DIEGO, Oct. 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S.
SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc.
NEW YORK, June 18, 2014 /PRNewswire-USNewswire/ -- With long-term use, the gold standard medication for Parkinson's disease, levodopa, can wear off before it's time for another dose, causing
DATA FROM KINECT 1 AND KINECT 2 TARDIVE DYSKINESIA STUDIES SAN DIEGO, June 11, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc.
EMERYVILLE, Calif., June 10, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc.
- An armed gangster.